INZY News
Archived Headlines
- Rare disease biotech Inozyme Pharma sets terms for $75 million IPO 07/20/20
- US IPO Week Ahead: A software provider and the largest SPAC ever take the spotlight in a diverse 7 IPO week 07/17/20
- US IPO Weekly Recap: 3 IPOs close out the 2Q in shortened holiday week 07/02/20
- Rare disease biotech Inozyme Pharma files for an $86 million IPO 07/02/20
US IPO Week Ahead: Foreign issuers dominate a 4 IPO week
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion...read more
US IPO Weekly Recap: Software and SPACs shine in a 7 IPO week
Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding (JAMF) and the largest SPAC ever Pershing Square Tontine Holdings (PSTHU). Four sizable biotechs all priced at the high end of...read more
Rare disease biotech Inozyme Pharma prices further upsized IPO at $16, in line with upwardly revised terms
Inozyme Pharma, a preclinical biotech developing protein therapies for rare calcification diseases, raised $112 million by offering 7 million shares at $16, in line with the upwardly revised terms. The company offered 0.5 million more shares than...read more
Rare disease biotech Inozyme Pharma increases proposed deal size by 39% ahead of $104 million IPO
Inozyme Pharma, a preclinical biotech developing therapies for diseases of abnormal mineralization, raised the proposed deal size for its upcoming IPO on Thursday. The Boston, MA-based company now plans to raise $104 million by offering 6.5 million shares...read more